Amit Kumar, Chief Executive Officer at Anixa Biosciences Inc (ANIX), bought 3,000 shares at $3.73 ($11K) on 2026-07-24, disclosed to the SEC on 2026-07-27.
CEO Amit Kumar purchased 3,000 shares of Anixa Biosciences for $11,190, signaling confidence in the company's oncology pipeline and recent analyst upgrades. This insider buying comes as the stock has rallied significantly over the last month, potentially indicating a bottoming out of the recent pullback.
The stock is down 0.58% over the last 5 days but has surged 24.41% over the past 30 days, trading at $3.44, which is 36.96% below its 52-week high of $5.4566.
1) Zacks upgraded ANIX to a Strong Buy on July 22, 2026, citing growing earnings optimism. 2) The company views 2026 as a 'pivotal year' for advancing its breast cancer vaccine and CAR-T therapies, as noted by CEO Amit Kumar on February 10, 2026. 3) Anixa secured a Korean patent for its breast cancer vaccine on June 30, 2026, expanding its IP portfolio.
The stock is currently trading 45.15% above its 52-week low of $2.37, which may indicate that the recent rally has already priced in some optimism, leaving less room for error if clinical data disappoints.
Nothing distinguishes this filing.
| Filing → |
| ANIX | BUY | 2026-09-11 | $14K | — | Filing → |
| ANIX | BUY | 2026-08-03 | $17K | — | Filing → |
| ANIX | BUY | 2026-07-28 | $17K | — | Filing → |